The Princeton Catalysis Initiative (PCI) has entered into its first collaboration with industry, signing Celgene to a 10-year, $6 million commitment. PCI aims to advance research from across the University in which catalysis is a key technological driver in solutions to problems of "increasing social concern," such as "the development of alternative energy technologies, environmental remediation strategies, access to novel pharmaceuticals and antibiotics, sustainable agriculture and renewable soft materials."
“PCI will be an academic incubator for new fields of research that will have significant benefit for society. Princeton is uniquely positioned to be the leader in this movement and in collaboration with Celgene we expect to make discoveries that will significantly impact human health over the next 10 years and beyond,” said David MacMillan, James S. McDonnell Distinguished University Professor of Chemistry and Director of PCI. “Celgene brings much more than funding — collaborators, ideas, and new opportunities for innovation and cross pollination.”
The agreement was announced by the University.
If you are interested in finding out more about PCI and how your company can get involved, contact Corporate Engagement Director Coleen Burrus. (Email; 609-258-5954)